Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

EHA 2019: The future of CML therapy: unmet medical needs and new treatments in development (Michael Mauro)

Michael Mauro EHA 2019

 

The Future of CML Therapy: Unmet Medical Needs and New Treatments in Development
Professor Michael Mauro, Memorial Sloan Kettering Cancer Center New York, USA 

  • Unmet needs in CML: TKI and SCT
  • TKI's in development for CML
  • Development of Asciminib for CML
  • ABL 001X2101: A multicenter, phase 1, first-in-human study
    •  Allosteric inhibition of BCR-ABL
    •  ABL 001X2201: T315l cohort
    • Asciminib phase 3 study Design NCT 03106779
    • Asciminib Phase 2 study design:
      Add-on to first-line imatinib for DMR NCT 03578367
  • PF-114: 3rd generation BCR-ABL
 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre. 

EHA 2019: Current treatment approaches in CML (Gianantonio Rosti)

Rosti EHA 2019


Current Treatment Approaches in CML
Professor Gianantonio Rosti, University of Bologna, Italy 

  • The natural course of CML
  • A conceptional model for progression for CML
  • The weight of the choice of 1st line treatment:
    2014 vs. 2019
  • Finding the track for 1st line TKI
    • Reaching earlier milestones of response
    • The disease risk
    • Is the patient 'eligible' for treatment discontinuation?
  • Facing a treatment failure
  • Take home messages

 

 

 

This talk was first presented during the Education Session on Chronic Myeloid Leukemia at EHA. You will find more education materials from EHA at the EHA Learning Centre. 

EHA 2019: CML treatment in the era of operational cure: Considerations for therapy selection (Giuseppe Saglio)

 

Saglio EHA 2019 CML Treatment in the Era of Operational Cure: Considerations for Therapy Selection
Professor Giuseppe Saglio, University of Turin, Italy
 
  • Clinical case: Women, 39 years old including;
    • Considerations for prognosis
    • Considerations on the possibility of TFR
  • ENESTnd study - 5 year update including cumulative incidence of MR4.5
  • Nilotinib is the only TKI registered for discontinuation
  • Summary of Steering Group recommendations derived from patient-physician discussion
  • Conclusion 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre. 

EHA 2019: TKI safety (Henrik Hjorth-Hansen)

Hjort Hansen EHA 2019


Safety of Tyrosine Kinase Inhibitors (TKI's) in CML
Professor Henrik Hjorth-Hansen, Norwegian University of Science and Technology, Trondheim, Norway 

  • Patient Case with Treatment Courses on IM, DAS, NIL, and BOS
  • Overview of TKI side effects and management
    • Imatinib side effects - IRIS trial
    • Dasatinib - what to expect?
    • Pleural effusions - what to do?
    • Nilotinib - what to expect and what to do?
    • Cardiovascular risk determiniation
    • Bosuntinib - what to expect?
  • Patient case with treatment courses on IM, DAS, NIL and BOS
  • Practical advice

 

This talk was first presented during the Education Session on Chronic Myeloid Leukemia at EHA. You will find more education materials from EHA at the EHA Learning Centre. 

EHA 2019: Special aspects in children (Fréderic Millot)

Millot EHA 2019

Mechanisms for Resistance and TFR in CML: Special Aspects in Children
Professor Fréderic Millot, University of Poitiers, France 

  • Clinical and biological characteristics of childhood CML
  • Mechanisms of failure of tyrosine kinase inhibitors in children with CML
  • Criteria for discontinuation of tyrosine kinase inhibitors in children with CML
  • Childhood CML: Conclusion

 

 

This talk was first presented during the Hematology-in-Focus Session on 'Mechanisms for resistance and treatment-free remission (TFR) in CML' at EHA. You will find more education materials from EHA at the EHA Learning Centre. 

EHA 2019: NGS in CML - new standard diagnostic procedure? (Susan Branford)

EHA 2019 Branford

NGS in CML - New Standard Diagnostic Procedure?
Associate Professor Susan Branford, Centre for Cancer Biology Adelaide, Australia 

  • CML is a genetically uniform disease: BCR-ABL1
  • Catalogue of somatic mutations in cancer: COSMIC
  • Sanger sequencing is impractical for broad discovery
  • Association of mutated cancer genes and transformation
  • New therapies for BC based on mutation profile
  • Other genes not listed in the cancer gene census?
  • Multiple genomic events may impact outcome

This talk was first presented during the Education Session on Chronic Myeloid Leukemia at EHA. You will find more education materials from EHA at the EHA Learning Centre.